mRNA + CRISPR: How COVID Vaccine Technology Powers Gene Editing

The Pandemic's Unexpected Gift to Gene Editing

When billions of people rolled up their sleeves for a COVID-19 vaccine in 2021, most had no idea they were participating in one of the largest proof-of-concept experiments in the history of genetic medicine. The Pfizer-BioNTech and Moderna vaccines did not merely protect against a virus. They validated a delivery platform -- lipid nanoparticles carrying messenger RNA -- that scientists had been quietly developing for decades. That platform is now being repurposed to deliver gene-editing tools directly into the human body.

The story of how a pandemic response accelerated gene editing by perhaps a decade is one of scientific convergence: decades of mRNA research, chemistry breakthroughs in lipid formulation, and the maturation of CRISPR gene-editing technology all arrived at the same moment. What follows is a deep exploration of how these threads came together, where the technology stands today, and why researchers believe we are entering a new era of in vivo genetic medicine.

Diagram of a lipid nanoparticle (LNP). The four-component lipid shell protects fragile mRNA cargo and facilitates cellular uptake. Image: Wikimedia Commons, CC BY-SA 4.0.

The Basics: What Is a Lipid Nanoparticle?

A lipid nanoparticle, or LNP, is a tiny sphere roughly 80 to 100 nanometers in diameter -- about one-thousandth the width of a human hair. It is composed of four lipid components, each serving a specific function:

1. Ionizable lipids are the workhorses of the particle. At neutral pH (like the bloodstream), these lipids carry no charge, which helps the LNP avoid immune detection. But when the LNP enters a cell and encounters the acidic environment of an endosome (pH ~5-6), the ionizable lipids become positively charged. This charge shift destabilizes the endosomal membrane, releasing the RNA cargo into the cytoplasm where it can do its work. The development of optimized ionizable lipids -- particularly Moderna's SM-102 and BioNTech/Acuitas Therapeutics' ALC-0315 -- was critical to vaccine success [1].

2. PEG-lipid (polyethylene glycol-conjugated lipid) forms a hydrophilic "stealth" coating on the particle's surface. This PEG layer prevents the immune system from recognizing and destroying the LNP before it reaches its target. However, PEG-lipid is a double-edged sword: too much prevents cellular uptake, and pre-existing anti-PEG antibodies in some individuals can trigger allergic reactions. Typically, PEG-lipid makes up only about 1.5% of the total lipid composition [2].

3. Cholesterol provides structural stability, filling gaps between the other lipids and making the particle more rigid. It also plays a role in membrane fusion during endosomal escape.

4. DSPC (distearoylphosphatidylcholine) is a helper lipid that contributes to the structural integrity of the LNP's outer shell, mimicking the phospholipid bilayer of natural cell membranes.

Together, these four components self-assemble around a nucleic acid payload -- whether that payload is mRNA encoding a viral spike protein or mRNA encoding the Cas9 gene-editing enzyme. The chemistry is remarkably versatile.

"The beauty of the LNP platform is its modularity," said Pieter Cullis, a University of British Columbia biochemist widely regarded as the father of lipid nanoparticle technology. "You can change what is on the inside without fundamentally redesigning the delivery vehicle" [3].

Katalin Kariko and Drew Weissman: The mRNA Breakthrough

The COVID vaccines would not exist without a discovery made in 2005 by Katalin Kariko and Drew Weissman at the University of Pennsylvania. For years, researchers had struggled with a fundamental problem: synthetic mRNA injected into the body triggered a violent inflammatory immune response. The immune system recognized the foreign mRNA and attacked it before it could be translated into protein.

Kariko and Weissman discovered that replacing one of the four nucleosides in mRNA -- uridine -- with a modified version called pseudouridine (or, more precisely, N1-methylpseudouridine) dramatically reduced this inflammatory response. The modified mRNA slipped past the innate immune system's toll-like receptors while still being efficiently translated by ribosomes into protein [4].

This seemingly modest chemical tweak was transformative. It meant that mRNA could be used as a therapeutic tool, not just a laboratory curiosity. Both Moderna and BioNTech built their vaccine platforms on this nucleoside-modified mRNA technology. Kariko and Weissman were awarded the Nobel Prize in Physiology or Medicine in 2023 for their discovery.

"For decades, mRNA was considered too unstable and too immunogenic for clinical use," Kariko reflected after receiving the Nobel. "We showed that with the right modifications, you could turn it into a powerful tool for medicine" [5].

Their work also laid the foundation for using modified mRNA to deliver gene-editing instructions. If you can use mRNA to instruct cells to make a viral spike protein, you can also use it to instruct cells to make a Cas9 enzyme -- the molecular scissors of CRISPR.

How COVID Vaccines Validated the Platform

The speed and scale of the COVID vaccine rollout provided something that decades of preclinical research could not: massive real-world safety and efficacy data for LNP-delivered mRNA.

Before COVID, LNPs had been validated in one FDA-approved drug: patisiran (Onpattro), approved in 2018 for a rare hereditary condition called transthyretin amyloidosis. Patisiran used LNPs to deliver small interfering RNA (siRNA) to the liver. But it was a niche therapy, administered to a small patient population by intravenous infusion [6].

The COVID vaccines changed everything. By mid-2023, more than 13 billion doses of COVID vaccines had been administered globally, with the mRNA vaccines from Pfizer-BioNTech and Moderna accounting for a substantial fraction. This generated an unprecedented safety database. Researchers could now point to billions of administered doses as evidence that LNP-mRNA technology was fundamentally safe and manufacturable at scale.

The COVID-19 vaccination campaign demonstrated that LNP-delivered mRNA could be manufactured and administered at global scale. Photo: Unsplash.

Moderna's chief medical officer, Paul Burton, stated in 2023: "COVID proved that this platform works in humans at a scale nobody imagined. Every gene therapy company in the world took notice" [7].

The validation went beyond safety. The vaccines demonstrated that LNPs could be manufactured rapidly using microfluidic mixing technology, stored at manageable temperatures (Moderna's vaccine was stable at standard freezer temperatures), and produced at a cost that, while not cheap, was within reach. These were exactly the manufacturing challenges that had stalled gene therapy for years.

The Pivot: From Vaccines to Gene Editing

The conceptual leap from COVID vaccines to CRISPR delivery is straightforward but profound. In a vaccine, LNPs carry mRNA that encodes a viral protein. In a gene-editing therapy, LNPs carry mRNA that encodes the Cas9 enzyme plus a synthetic guide RNA that directs Cas9 to a specific location in the genome.

There is, however, a critical difference that makes mRNA delivery of CRISPR potentially safer than the traditional approach.

The Transient Expression Advantage

When CRISPR components are delivered via mRNA inside an LNP, the mRNA is translated into Cas9 protein by the cell's ribosomes. The Cas9 makes its edit, and then the mRNA degrades naturally -- typically within 24 to 48 hours. The Cas9 protein itself is cleared shortly afterward. This means the editing machinery is only present in the cell temporarily.

Compare this to delivery via adeno-associated virus (AAV), the most established viral vector for gene therapy. AAV delivers DNA encoding Cas9, which can persist in the cell for months or even years as an episome (an extra-chromosomal DNA element). Prolonged Cas9 expression raises significant safety concerns:

• Increased off-target editing: The longer Cas9 is active, the more opportunities it has to cut DNA at unintended locations
• Immune responses: Sustained production of a bacterial protein (Cas9 originates from Streptococcus pyogenes) can trigger adaptive immune responses, including T-cell mediated destruction of edited cells
• Dose limitations: AAV vectors can only be administered once due to anti-AAV antibodies, while LNPs can theoretically be re-dosed

"The hit-and-run nature of mRNA delivery is one of its greatest advantages," explained Jennifer Doudna, co-inventor of CRISPR and Nobel laureate. "You want the editor to do its job and then disappear. You don't want it hanging around indefinitely" [8].

LNP-CRISPR vs. AAV Delivery: A Comparison

Feature	LNP-mRNA Delivery	AAV Viral Delivery
Cas9 expression duration	Transient (24-48 hours)	Prolonged (months to years)
Redosing	Possible	Typically one-time due to immune response
Cargo capacity	Essentially unlimited	~4.7 kb (tight for Cas9 + guide RNA)
Manufacturing	Chemical process, scalable	Biological process, complex
Immunogenicity	Lower (lipids are generally well tolerated)	Higher (viral capsid triggers immune response)
Primary organ targeting	Liver (default), expanding	Varies by serotype
Integration risk	None (mRNA cannot integrate)	Low but nonzero

Gene therapy delivery vectors compared. LNPs represent the leading non-viral approach, avoiding the cargo size limitations and immunogenicity challenges of viral vectors like AAV. Image: Wikimedia Commons, CC BY-SA 4.0.

Intellia Therapeutics: The First In Vivo CRISPR Edit

The company that first proved LNP-delivered CRISPR could work inside the human body was Intellia Therapeutics, co-founded by Jennifer Doudna. In June 2021 -- while COVID vaccines were still being distributed worldwide -- Intellia reported interim results from the first clinical trial of an in vivo CRISPR therapy.

The trial targeted transthyretin amyloidosis (ATTR), the same disease treated by patisiran. In ATTR, misfolded transthyretin protein accumulates in organs, causing progressive damage to the heart and nerves. Intellia's therapy, called NTLA-2001, used LNPs to deliver Cas9 mRNA and a guide RNA to the liver, where they knocked out the TTR gene responsible for producing the misfolded protein.

The results were striking. A single intravenous infusion reduced serum TTR protein levels by up to 87% at the lower dose and 96% at the higher dose. Subsequent follow-up data showed that these reductions were durable, lasting more than two years with no significant safety concerns [9].

"This was the moment the field had been waiting for," said John Leonard, president and CEO of Intellia. "We showed that you could deliver CRISPR systemically, make a precise edit in the liver, and achieve a clinically meaningful result with a single dose" [10].

Intellia's success validated the entire LNP-CRISPR paradigm. The company used ionizable lipids similar in concept (though proprietary in composition) to those in the COVID vaccines. The same basic chemistry that delivered spike protein instructions to arm muscle cells was now delivering gene-editing instructions to hepatocytes.

Clinical Programs: Who Is Doing What

The success of NTLA-2001 opened the floodgates. Multiple companies are now running clinical programs that use LNP-delivered CRISPR or related editing technologies:

Intellia Therapeutics

Beyond ATTR amyloidosis, Intellia is advancing NTLA-2002 for hereditary angioedema (HAE), a condition involving painful swelling episodes caused by excess kallikrein activity. The therapy uses LNP-CRISPR to knock out the KLKB1 gene in the liver. Phase 2 data presented in 2024 showed near-complete elimination of swelling attacks in most patients [11].

Verve Therapeutics

Verve is pursuing what may be the most audacious application of LNP-delivered gene editing: a one-time treatment for heart disease. Their lead program, VERVE-102, uses LNP-delivered base editing (a refined form of CRISPR that changes single DNA letters without cutting the double strand) to permanently inactivate the PCSK9 gene in liver cells. PCSK9 regulates LDL cholesterol; turning it off mimics a naturally occurring protective mutation found in some humans who have very low cholesterol and reduced heart disease risk. Early clinical data showed significant LDL cholesterol reduction [12].

CRISPR Therapeutics

Known primarily for Casgevy (the first approved CRISPR therapy, used ex vivo for sickle cell disease), CRISPR Therapeutics is also developing in vivo LNP-CRISPR programs. CTX310, their anti-ANGPTL3 therapy for cardiovascular disease, uses LNPs to deliver CRISPR to the liver to reduce triglycerides and LDL cholesterol. The program entered clinical trials in 2024 [13].

The CHOP Breakthrough: Personalized LNP-Base Editing

Perhaps the most remarkable demonstration of this technology's potential came from the Children's Hospital of Philadelphia (CHOP) in early 2025. A team led by Kiran Musunuru used LNP-delivered base editing to treat an infant named KJ with severe cardiomyopathy caused by a mutation in the CMP gene.

The therapy was designed, manufactured, and administered in a matter of months -- an unprecedented timeline for a personalized genetic medicine. The LNPs delivered base editor mRNA and a custom guide RNA to KJ's liver cells, correcting the disease-causing mutation. Early reports indicated cardiac improvement [14].

This case demonstrated something that had long been theoretical: the LNP platform could be rapidly customized for individual patients. Because the manufacturing process is chemical rather than biological, swapping in a different guide RNA sequence to target a different mutation is relatively straightforward compared to redesigning a viral vector.

Modern gene therapy manufacturing relies on chemical processes that are faster and more scalable than traditional viral vector production. Photo: Unsplash.

Organ-Selective LNPs: Beyond the Liver

There is a significant challenge facing LNP-CRISPR therapy: the liver problem. When administered intravenously, conventional LNPs overwhelmingly accumulate in the liver. This is because apolipoprotein E (ApoE) in the bloodstream adsorbs onto the LNP surface and directs the particles to ApoE receptors on hepatocytes.

For liver diseases like ATTR amyloidosis, this natural tropism is an advantage. But most genetic diseases affect other organs -- the lungs, brain, muscles, heart, or kidneys. Reaching these tissues requires engineering LNPs that can evade the liver's gravitational pull.

SORT Technology

One of the most promising approaches is Selective Organ Targeting (SORT), developed by Daniel Siegwart's lab at the University of Texas Southwestern Medical Center. SORT works by adding a fifth lipid component to the standard four-component LNP formulation. By varying the charge and proportion of this additional lipid, researchers can redirect LNPs to different organs [15].

• Adding a permanently cationic lipid (like DOTAP) at 50% molar ratio shifts delivery to the lungs
• Adding an anionic lipid (like 18PA) at 30% molar ratio shifts delivery to the spleen
• Varying the percentage fine-tunes the ratio of delivery between organs

"We showed that by simply changing the lipid composition, you can dial in delivery to the liver, lungs, or spleen," Siegwart explained. "This opens up gene editing to a much wider range of diseases" [15].

SORT technology has been licensed to multiple companies and is advancing toward clinical translation. In preclinical studies, SORT-LNPs have achieved functional gene editing in lung epithelial cells, potentially opening the door to CRISPR-based treatments for cystic fibrosis and lung cancer.

Other Approaches

Several additional strategies are being explored to solve organ targeting:

• Antibody-conjugated LNPs: Attaching targeting antibodies or peptides to the LNP surface to direct them to specific cell types
• Nebulized delivery: Inhaling LNPs directly into the lungs, bypassing systemic circulation entirely. Intellia has a preclinical program using nebulized LNP-CRISPR for lung diseases
• Intrathecal injection: Delivering LNPs directly into the cerebrospinal fluid for central nervous system conditions
• Engineered PEG alternatives: Replacing PEG-lipid with alternative stealth coatings that may reduce allergic reactions while maintaining circulation time

Despite these advances, lung and brain delivery remain substantial challenges. The blood-brain barrier, in particular, has proven extraordinarily difficult to cross with LNPs. Most central nervous system programs still rely on direct injection rather than systemic delivery.

How mRNA Delivery of Cas9 Actually Works

For those interested in the molecular mechanics, here is a step-by-step walkthrough of how LNP-delivered CRISPR editing works inside the body:

Step 1: Formulation. Cas9-encoding mRNA and synthetic guide RNA (sgRNA) are mixed with the four lipid components using a microfluidic mixing device. The lipids spontaneously self-assemble around the RNA at low pH, forming nanoparticles of uniform size.

Step 2: Administration. The LNPs are administered by intravenous infusion. For liver-targeted therapies, the infusion typically takes about one hour.

Step 3: Circulation and uptake. In the bloodstream, ApoE adsorbs onto the LNP surface. ApoE-coated LNPs are recognized by LDL receptors on hepatocytes and taken up via receptor-mediated endocytosis.

Step 4: Endosomal escape. Inside the cell, the LNP is trapped in an endosome -- a membrane-bound compartment with an acidic interior. The ionizable lipids become protonated (positively charged) at the low endosomal pH, interacting with negatively charged endosomal membrane lipids. This interaction destabilizes the endosome, releasing the mRNA and sgRNA into the cytoplasm.

Step 5: Translation. Ribosomes in the cytoplasm translate the Cas9 mRNA into Cas9 protein. Because the mRNA uses N1-methylpseudouridine (Kariko and Weissman's modification), it avoids triggering an innate immune response and is translated efficiently.

Step 6: Nuclear entry. The Cas9 protein, complexed with the guide RNA, enters the nucleus through nuclear pores. The guide RNA directs the Cas9 to its target DNA sequence through Watson-Crick base pairing.

Step 7: Gene editing. Cas9 creates a double-strand break at the target site (or, in the case of base editors, makes a precise single-base change without cutting). The cell's DNA repair machinery processes the break, typically inactivating the target gene through insertions or deletions.

Step 8: Cleanup. The mRNA degrades within 24-48 hours. The Cas9 protein is cleared by normal cellular protein degradation pathways. The gene edit, however, is permanent and heritable by daughter cells.

Challenges and Limitations

Despite the extraordinary progress, significant challenges remain before LNP-CRISPR therapies become broadly available:

The Liver Ceiling

As discussed, conventional LNPs naturally home to the liver. While this is ideal for metabolic and cardiovascular diseases, it excludes the majority of genetic conditions. Reaching the muscles (for Duchenne muscular dystrophy), the brain (for Huntington's disease), or the lungs (for cystic fibrosis) with systemically administered LNPs remains an unsolved problem for clinical use.

Immune Responses to LNPs

While generally well-tolerated, LNPs are not immunologically inert. The PEG-lipid component can trigger complement activation-related pseudoallergy (CARPA) in some patients, causing infusion-related reactions. Anti-PEG antibodies, present in a meaningful fraction of the population due to widespread PEG use in cosmetics and medications, may reduce efficacy upon repeat dosing [16].

Manufacturing Complexity

Although LNP manufacturing is simpler than viral vector production, formulating LNPs that consistently encapsulate the correct ratio of Cas9 mRNA and guide RNA remains technically demanding. Batch-to-batch variability, cold chain requirements, and the need for specialized microfluidic equipment add cost and complexity.

Editing Efficiency and Precision

Current LNP-CRISPR therapies work best for knockout applications -- inactivating a gene -- because non-homologous end joining (the cell's primary double-strand break repair pathway) efficiently disrupts gene function. Precise insertions or corrections via homology-directed repair remain much less efficient in vivo, limiting the range of treatable diseases.

Regulatory and Ethical Considerations

The permanence of gene editing raises unique regulatory questions. Unlike a drug that can be discontinued if side effects emerge, a gene edit cannot be reversed. Regulatory agencies like the FDA are developing new frameworks for evaluating these therapies, including long-term follow-up requirements of 15 years or more for gene-editing clinical trials [17].

The DNA double helix. CRISPR gene editing targets specific sequences within this structure, making precise changes that are permanent and heritable by daughter cells. Image: Wikimedia Commons, CC BY-SA 3.0.

The Future: Where LNP-CRISPR Is Heading

The convergence of mRNA technology and CRISPR is still in its early chapters. Several developments are likely to shape the next decade:

Multiplexed editing. Researchers are exploring whether LNPs can deliver multiple guide RNAs simultaneously, enabling edits at several genomic locations in a single treatment. This could be particularly relevant for polygenic diseases or for creating more effective CAR-T cells.

Prime editing delivery. Prime editors, which can make all 12 possible base-to-base conversions plus small insertions and deletions without double-strand breaks, are being packaged into LNPs. The challenge is size: prime editor mRNA is substantially larger than Cas9 mRNA, requiring larger or more efficient LNPs.

Epigenetic editing. Rather than permanently altering the DNA sequence, epigenetic editors use deactivated Cas9 (dCas9) fused to epigenetic modifiers to turn genes on or off without changing the genetic code. Delivered via LNPs, these could offer a reversible alternative to permanent gene editing.

Repeat dosing strategies. For diseases where a single dose does not achieve sufficient editing, researchers are exploring whether LNP-CRISPR can be administered multiple times. Early evidence suggests this is feasible, though anti-LNP immune responses must be managed.

Point-of-care manufacturing. The CHOP case demonstrated that personalized LNP therapies could be manufactured in months. As the technology matures, this timeline could shrink to weeks, enabling truly individualized genetic medicines for ultra-rare diseases.

Non-liver delivery at scale. Multiple academic labs and companies are racing to develop LNPs that reliably reach the lungs, brain, heart, and muscle. Success in any of these organs would dramatically expand the treatable disease landscape.

What the Pandemic Taught Us

COVID-19 was a catastrophe by any measure. But it also served as an accidental accelerant for a technology platform that may ultimately prove more consequential than the vaccines themselves. Before the pandemic, LNP-mRNA technology was a promising but unproven concept for most applications. After the pandemic, it was a validated, scalable, and globally manufactured platform with a safety database encompassing billions of human exposures.

The lesson is one that science historians will study for decades: sometimes a crisis creates the conditions for breakthroughs that would otherwise have taken far longer to achieve. The same lipid nanoparticles that carried spike protein instructions to arm muscle cells are now carrying gene-editing instructions to liver cells, with other organs soon to follow.

Katalin Kariko, reflecting on the trajectory from her early mRNA research to COVID vaccines to gene editing, put it simply: "The mRNA was always the same. What changed was that the world finally saw what it could do" [5].

For patients with genetic diseases, that visibility may prove to be the pandemic's most lasting legacy.

---

Sources

1. Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). "Lipid nanoparticles for mRNA delivery." Nature Reviews Materials, 6, 1078-1094. https://doi.org/10.1038/s41578-021-00358-0

2. Schoenmaker, L., et al. (2021). "mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability." International Journal of Pharmaceutics, 601, 120586. https://doi.org/10.1016/j.ijpharm.2021.120586

3. Cullis, P. R., & Hope, M. J. (2017). "Lipid Nanoparticle Systems for Enabling Gene Therapies." Molecular Therapy, 25(7), 1467-1475. https://doi.org/10.1016/j.ymthe.2017.03.013

4. Kariko, K., Buckstein, M., Ni, H., & Weissman, D. (2005). "Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA." Immunity, 23(2), 165-175. https://doi.org/10.1016/j.immuni.2005.06.008

5. Nobel Prize. (2023). "Press release: The Nobel Prize in Physiology or Medicine 2023." https://www.nobelprize.org/prizes/medicine/2023/press-release/

6. Adams, D., et al. (2018). "Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis." New England Journal of Medicine, 379(1), 11-21. https://doi.org/10.1056/NEJMoa1716153

7. Moderna. (2023). "mRNA Platform: Enabling Drug Discovery & Development." https://www.modernatx.com/mrna-technology/mrna-platform-enabling-drug-discovery-development

8. Doudna, J. A. (2020). "The promise and challenge of therapeutic genome editing." Nature, 578, 229-236. https://doi.org/10.1038/s41586-020-1978-5

9. Gillmore, J. D., et al. (2021). "CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis." New England Journal of Medicine, 385(6), 493-502. https://doi.org/10.1056/NEJMoa2107454

10. Intellia Therapeutics. (2021). "Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein." Press release. https://ir.intelliatx.com/news-releases

11. Intellia Therapeutics. (2024). "NTLA-2002 Phase 2 Clinical Data for Hereditary Angioedema." https://www.intelliatx.com/our-pipeline/

12. Verve Therapeutics. (2023). "Verve Therapeutics Presents Clinical Data from heart-1 Trial." https://www.vervetx.com/programs-pipeline/

13. CRISPR Therapeutics. (2024). "CTX310 Clinical Program for Cardiovascular Disease." https://crisprtx.com/programs/cardiovascular-diseases

14. Musunuru, K. (2025). "Personalized base editing therapy for cardiomyopathy." Children's Hospital of Philadelphia. https://www.chop.edu/news

15. Cheng, Q., et al. (2020). "Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing." Nature Nanotechnology, 15, 313-320. https://doi.org/10.1038/s41565-020-0669-6

16. Kozma, G. T., et al. (2020). "Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals." Advanced Drug Delivery Reviews, 154-155, 163-175. https://doi.org/10.1016/j.addr.2020.07.024

17. FDA. (2022). "Human Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry." https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-products-incorporating-human-genome-editing